We are live on ! Find out more

Eupraxia Pharmaceuticals

EPRX

Market cap $455M

6.89 USD

+0.13

1.92%

At close Updated Nov 3, 3:59 PM EST

Pre-market

After hours

6.88

-0.01

0.15%

1 day

1.92%

5 days

-2.68%

1 month

-11.1%

3 months

5.84%

6 months

-7.14%

Year to date

-8.98%

1 year

13.14%

5 years

133.56%

10 years

133.56%

About: Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

Employees: 49

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 12.5%

Neutral 87.5%

Negative 0%

Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will participate in the following upcoming conferences and host a virtual Analyst Day: Craig Hallum Biotech Catalyst Virtual Conference (October 22 nd , 2026) Format: Fireside Chat & 1x1 Meetings Fireside Chat Date & Time: October 22, 2026, at 10:30am ET Webcast link: Here Location: Virtual BIO-Europe (November 9-11, 2026) Format: 1x1 Meetings Location: Cologne, Germany Stifel 2026 Healthcare Conference (November 10-12, 2026) Format: Fireside Chat & 1x1 Meetings Fireside Chat Date & Time: November 10, 2026, at 4:40pm ET Webcast Link: Here Location: New York, NY Virtual Analyst Day to Discuss EP-104GI for Eosinophilic Esophagitis (November 13 th , 2026) Format: Presentation Presentation Date & Time: November 13, 2026, at 8:30am ET Webcast Link: Here Location: Virtual 2026 Jefferies Global Healthcare Conference in London (November 16-19, 2026) Format: Presentation & 1x1 Meetings Presentation Date & Time: November 16, 2026, at 1:30pm GMT Webcast Link: Here Location: London, UK About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs.

Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day

Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target.

Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company's ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE") have been accepted and will be presented at: (i) the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting & Postgraduate Course, being held October 9-14, 2026 in Nashville, Tennessee, and (ii) the United European Gastroenterology (UEG) Week 2026, being held October 17-20, 2026 in Barcelona, Spain.

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced updated clinical data from the Phase 1b/2a RESOLVE study highlighting the long duration of response, high remission rates and tolerability of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”).

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced today that its common shares have commenced trading on the Nasdaq Global Select Market.

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatment In the same analysis, 23% of patients reported severe odynophagia at baseline; and no patients reported severe odynophagia at the 24 and 52 weeks timepoints The number of patients experiencing moderate to severe dysphagia (difficulty swallowing) in Cohorts 7-9 was reduced from 77% at baseline to 25% at 24 and 52 weeks post treatment At baseline 31% of patients in Cohorts 7-9 had severe dysphagia; no patients had severe dysphagia at 24 and 52 weeks post treatment EP-104GI continues to be well tolerated by patients receiving the drug. There have been over 130 patients treated in RESOLVE with EP-104GI or placebo (more than 2,000 individual injection sites) with no reported treatment-emergent or procedure related Serious Adverse Events (“SAEs”) VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced positive results from a new analysis of the RESOLVE study examining the effect of EP-104GI on symptom severity, including for the first time an analysis of the effect of EP-104GI on odynophagia (pain when swallowing).

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Zacks Investment Research

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?

The consensus price target hints at a 145.4% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced updates to its executive leadership and operating structure as the Company continues to prepare for its next stage of clinical and commercial development.

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization

VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. "We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization

See News Rankings

Price charts implemented using Lightweight Charts™